| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Hydrastinine hydrochloride targets various molecular targets. It has been shown to have uterotonic effects, suggesting activity at receptors or ion channels involved in uterine smooth muscle contraction. The compound's isoquinoline structure suggests potential interactions with neurotransmitter receptors, ion channels, or enzymes. Some studies have investigated its potential anticancer activity, suggesting effects on cell proliferation or apoptosis pathways. The compound's specific molecular targets are not fully characterized, and further research is needed to elucidate its mechanism of action. As a derivative of hydrastine, it may share some of the pharmacological properties of the parent compound.
|
|---|---|
| ln Vitro |
Numerous ailments, including as inflammation, gastrointestinal issues, and urinary tract issues, have been treated using goldenseal. Berberine, palmatine, hydrastine, canadine, and hydrastine are the five primary alkaloid components found in goldenseal[1].
In vitro studies have demonstrated that hydrastinine hydrochloride has uterotonic effects, stimulating uterine smooth muscle contraction. The compound has also been investigated for potential anticancer activity, with studies suggesting effects on cancer cell proliferation or apoptosis. The compound's isoquinoline structure suggests potential interactions with various biological targets. Detailed in vitro activity data, including specific IC50 values or binding affinities, are limited in the available literature. The compound's in vitro effects are concentration-dependent and have been studied in various cell-based and tissue-based assays. |
| ln Vivo |
In vivo studies have demonstrated the uterotonic effects of hydrastinine hydrochloride, with the compound stimulating uterine contractions. This property has been investigated for potential applications in obstetrics and gynecology. The compound has also been studied for its potential anticancer activity in animal models. However, detailed in vivo data for hydrastinine hydrochloride are limited in the available literature. The compound is a research chemical and is not currently approved for clinical use. Its in vivo effects and therapeutic potential require further investigation.
|
| Enzyme Assay |
The in vitro receptor binding assay for hydrastinine hydrochloride would depend on the specific biological target being studied. For uterotonic activity, the compound's effects on uterine smooth muscle contraction can be assessed using isolated uterine tissue preparations. Uterine strips from rodents are mounted in organ baths and contractile responses to varying concentrations of hydrastinine hydrochloride (typically 0.001-100 uM) are measured using force transducers. The compound's effects on calcium channels or other ion channels can be assessed using patch-clamp electrophysiology. For anticancer studies, the compound's effects on cell proliferation are assessed in cancer cell lines. The specific assay protocol depends on the research question and the target being investigated.
|
| Cell Assay |
In vitro cellular assays for hydrastinine hydrochloride are conducted using various cell lines depending on the research application. For anticancer studies, cancer cells are seeded in 96-well plates and treated with varying concentrations of hydrastinine hydrochloride (typically 0.1-100 uM) for 24-72 hours. Cell viability is assessed using MTT, CellTiter-Glo, or crystal violet staining assays. Apoptosis is evaluated using Annexin V-FITC/PI double staining or by measuring caspase activity. For uterotonic studies, uterine smooth muscle cells are used, and contractility or calcium mobilization is measured. The specific assay depends on the research question and the cell type being studied. Cell viability is monitored to ensure that observed effects are not due to cytotoxicity.
|
| Animal Protocol |
In vivo animal studies for hydrastinine hydrochloride typically involve administration to rodents to assess its uterotonic effects or anticancer activity. For uterotonic studies, pregnant or non-pregnant female rodents are administered hydrastinine hydrochloride by intravenous, intraperitoneal, or subcutaneous injection at doses ranging from 0.1-10 mg/kg. Uterine contractions are measured using intrauterine pressure transducers or by assessing the effects on pregnancy outcomes. For anticancer studies, mice bearing xenograft tumors are treated with hydrastinine hydrochloride and tumor growth is monitored. Specific protocols depend on the research question and the effects being studied. Detailed protocols for this compound are limited in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of hydrastinine hydrochloride have not been extensively characterized. The compound has a molecular weight of 241.67 and a molecular formula of C11H12ClNO3. As a hydrochloride salt, it is expected to have good aqueous solubility. The compound is a research chemical and is not currently used as a therapeutic agent. Detailed ADME parameters including half-life, bioavailability, and plasma protein binding are not extensively documented in the available literature. The compound should be stored under appropriate conditions as recommended by the supplier.
|
| Toxicity/Toxicokinetics |
The toxicological profile of hydrastinine hydrochloride has not been extensively characterized. As an isoquinoline alkaloid derivative, the compound may have effects on smooth muscle, the cardiovascular system, and the nervous system. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions should be followed when handling the compound in a laboratory setting. No specific LD50 values or detailed toxicity profiles have been reported. The compound's uterotonic effects suggest that it should be handled with care, particularly in the context of reproductive studies.
|
| References | |
| Additional Infomation |
Hydrastinine hydrochloride (CAS 4884-68-8) is a synthetic derivative of hydrastine, an isoquinoline alkaloid found in Hydrastis canadensis (goldenseal) and other plants. The compound is the hydrochloride salt of hydrastinine, which is the reduced form of hydrastine. Hydrastinine hydrochloride has been studied for its uterotonic (uterine-stimulating) effects and potential anticancer activity. It has been used in traditional medicine and as a research compound. The compound's isoquinoline structure suggests potential interactions with various biological targets, including neurotransmitter receptors, ion channels, and enzymes. It is available for research purposes only.
|
| Molecular Formula |
C11H14CLNO3
|
|---|---|
| Molecular Weight |
243.6868
|
| Exact Mass |
243.066
|
| CAS # |
4884-68-8
|
| Related CAS # |
Hydrastinine;6592-85-4
|
| PubChem CID |
71833
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
342.5ºC at760mmHg
|
| Flash Point |
161ºC
|
| LogP |
1.634
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
248
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DLNQCQJCIITVHC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H13NO3.ClH/c1-12-3-2-7-4-9-10(15-6-14-9)5-8(7)11(12)13;/h4-5,11,13H,2-3,6H2,1H3;1H
|
| Chemical Name |
6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-ol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~341.95 mM)
H2O : ~50 mg/mL (~205.18 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.54 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.54 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.54 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10 mg/mL (41.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1036 mL | 20.5179 mL | 41.0357 mL | |
| 5 mM | 0.8207 mL | 4.1036 mL | 8.2071 mL | |
| 10 mM | 0.4104 mL | 2.0518 mL | 4.1036 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
